Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Centre Hospitalier Emile Roux | OTHER |
| Centre de Recherche en Nutrition Humaine d'Auvergne | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The main objective of the study is to determine the influence of patient sera before and after probiotic intervention on the behavior of bone cells (osteoblasts and osteoclasts).
The secondary objectives are to assess the activity of bone cells and the course of rheumatoid arthritis before and after the consomption of probiotics.
The written consent of the subjects will be obtained after full information of the aims, nature and possible risks of the study.
Before inclusion, subjects will undergo a medical check-up including an interview on personal and family history and drug treatments taken as well as a standard medical examination including weight, height and blood pressure measurement. . Their compliance with the inclusion / exclusion criteria will be verified during this review. An interview with personnel involved in the research (a dietician / study Research clinic assistant, etc.) will also be carried out as well as a biological selection assessment.
As part of this study, the subjects will come a total of 7 times to the Emile ROUX hospital in Le Puy en Velay.
The probiotic treatment will begin between 1 and 3 weeks after the inclusion visit. The volunteers / patients recruited will have a volume of blood sampled and a stool collected before the start of the probiotic treatment (T = 0) and at the end of the treatment (T = 4 weeks). The study consists of three periods of probiotic treatment of 4 weeks each interspersed with a wash-out period of 3 weeks in accordance with the recovery period necessary between two blood samples.
The sera thus obtained will then be analyzed to determine their biological activity with regard to the induction of changes in the behavior of bone cell models: osteoformin cells (osteoblasts) and osteo-resorbent cells (osteoclasts).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Traitement 1 | Experimental | Lactobacillus salivarius |
|
| Traitement 2 | Experimental | Lactobacillus Rhamnosus GG |
|
| Traitement 3 | Experimental | Bifidobacterium lactis |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| daily supplementation | Dietary Supplement | the patients will consume 1 pill of probiotic each day for 28 days per treatments each treatment is separated by a wash out period of 21 days |
| Measure | Description | Time Frame |
|---|---|---|
| Change of biological activity of serum between day 0 to day 28 | Ex vivo quantification of the formation of osteoclast multi-nucleated cells following culture in the presence of metabolites from the serum of patients between day 0 and day 28 | Day 0 and Day 28 |
| Measure | Description | Time Frame |
|---|---|---|
| Change of Disease Activity Score (DAS28) day 0 to day 28 | The Disease Activity Score (DAS) is a combined index to measure the disease activity in patients with rheumatoid arthritis (RA). Evaluation of a patient's response to treatment can be made much easier and more objective using the DAS28. (Twenty-eight tender and swollen joint scores include the same joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and the knees.) Simply assess the number of swollen and tender joints and measure the ESR. The DAS will provide you with a number between 0 and 10, indicating the activity rate of the rheumatoid arthritis is at that particular moment. |
Not provided
Inclusion Criteria:
Women
Exclusion Criteria:
Vaccination in the last two months
Alcohol abuse with regard to WHO standards
Smoking (>5 cigarettes/day)
-> 5 hours of intense sport per week
Food allergy and others
Antibiotic treatment in the month preceding inclusion
Persons under guardianship, curators, deprived of liberties, safeguard of justice
Refusal to sign the information and consent form
higher prevalency of RA in women
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| yohann wittrant, PhD | Contact | +33682297271 | yohann.wittrant@inrae.fr | |
| emilie gadea, PhD | Contact | responsable.rechercheclinique@ch-lepuy.fr |
| Name | Affiliation | Role |
|---|---|---|
| benjamin castagne, MD | Centre Hospitalier Emile Roux | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier Emile Roux | Recruiting | Le Puy-en-Velay | 43000 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
Crossover Assignment patient may receive 3 products in 3 interventions sequentially during the protocol
Not provided
Not provided
single blind
| Day 0 and Day 28 |
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |